Volume Therapy in Neurology

Treib, J.; Grauer, M; Haaß, A.

doi:10.1007/978-3-642-59621-6_1

Cited by 3 publications

(6 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These effects have been observed frequently in the past. Treib [2] reported a five-fold increase in serum amylase after a long-term infusion of HES 200/0.62, a starch which is difficult to break down.…”

Section: Discussionmentioning

confidence: 99%

“…This decreased storage in the RES is supported by the fact that the fibronectin concentration is not affected by HES 130/0.4. In an earlier study with HES 200/0.62, which is difficult to metabolize, a 50% decrease of fibronectin was observed [2].…”

Section: Discussionmentioning

confidence: 99%

“…Hypervolemic hemodilution attempts to optimize cerebral perfusion of ischemic regions through an optimization of rheological parameters and an increase in cardiac output and blood pressure [2,3,8,9]. Administration of volume optimizes ventricular filling and increases cardiac output via an increase in cardiac stroke volume without an increase in heart rate.…”

Section: Discussionmentioning

confidence: 99%

“…In patients with acute ischemic stroke, intravenous administration of volume is a generally accepted therapy regimen for the treatment hypovolemia and dehydration, which are often present [2,3]. In general, crystalloid solutions are used for this.…”

Section: Introductionmentioning

confidence: 99%

“…During recent decades, the issue of whether colloid or crystalloid solutions are preferable for volume replacement and volume therapy has been the subject of ongoing discussion [1,2]. In patients with acute ischemic stroke, intravenous administration of volume is a generally accepted therapy regimen for the treatment hypovolemia and dehydration, which are often present [2,3].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Influence of a Long-Term, High-Dose Volume Therapy with 6% Hydroxyethyl Starch 130/0.4 or Crystalloid Solution on Hemodynamics, Rheology and Hemostasis in Patients with Acute Ischemic Stroke

Woessner

Grauer

Dieterich

et al. 2003

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Background: This study was performed to investigate the clinical effects of a 4-day volume therapy with a newly developed, 6% hydroxyethyl starch (HES) 130/0.4 versus crystalloid solution, with particular regard to systemic and cerebral hemodynamics, rheology and safety. Methods: In a randomized, double-blind study, 40 patients suffering from an acute ischemic stroke received either 6% HES 130/0.4 or crystalloid solution as continuous infusion over 4 days with a total dose of 6.5 liters. Efficacy parameters studied included hemodynamics (cardiac output, blood pressure, flow velocity with transcranial Doppler) and rheology (hematocrit and plasma viscosity). Safety parameters examined included laboratory, hemostaseology (including factor VIII) and an adverse event questionnaire (including pruritus). Results: In both groups, a small, but not significant increase in cardiac output was observed. There were no significant changes regarding the remaining efficacy or safety parameters, except for the well-known increase in serum alpha-amylase through the infusion of HES. Conclusion: In our study with patients suffering from acute ischemic stroke, continuous infusion (1 ml/min) of HES 130/0.4 or crystalloid solution did not differ regarding safety or hemodynamic efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%